Variability in the prescription of cholinesterase inhibitors and memantine

Dementia and Geriatric Cognitive Disorders

Volumn 28, Issue 4, 2009, Pages 373-379

  Villar Fernandez I ^a   Bjerrum, L ^c   Feja, C ^a   Rabanaque, M J ^b  

^a INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Memantine; Pharmacoepidemiology; Treatment variability

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SPAIN; TOTAL QUALITY MANAGEMENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG COSTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; SPAIN;

EID: 70350525099     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253845     Document Type: Article

References (36)

1. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1:CD005593. DOI: 10.1002/ 14651858.CD005593. (Pubitemid 46841366)
2. McShane R, Areosa Sastre A, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006; 2:CD003154. DOI: 10.1002/14651858.CD003154.pub5.
3. Committee for medicinal products for human use post-authorisation summary of opinion for Axura. EMEA/CHMP/341426/ 2005. London, EMEA, 2005.
4. Villar Fernández I, Rabanaque Hernández MJ, Armesto Gómez J, García Arilla E, Izuel Rami M: Use of specific drugs for Alzheimer's disease. Neurologia 2007; 22: 275-284.
5. Therapeutics Initiative: Drug's for Alzheimer's disease. Therapeutics letter April-August 2005. http://www.ti.ubc.ca/pages/letter56. htm (accessed March 15, 2008).
6. Marion Buen J, Peiró S, Márquez Calderón S, Meneu de Guillerna R: Variaciones en la práctica médica: importancia, causas e implicaciones. Med Clin 1998; 110: 382-390.
7. Ward PR, Noyce PR, St Leger AS: Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors and beta-blockers: a crosssectional study in England. Ther Clin Risk Manag 2005; 1: 61-68.
8. Librero J, Rivas F, Peiró S, Allepuz A, Montes Y, Bernal-Delgado E, et al: Metodología en el Atlas VPM. Atlas VPM 2005; 1: 43-48.
9. Lobo A, Launer LJ, Fratiglioni L, Andersen K, di Carlo A, Breteler MM, et al: Prevalence of dementia and major subtypes in Europe: a collaborative study of population based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54(suppl 5): S4-S9. (Pubitemid 30390598)
10. Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465-479.
11. Richie K, Kildea D, Robine JM: The relationship between age and prevalence of senile dementia: a meta-analysis of recent data. Int J Epidemiol 1992; 21: 763-769.
12. Portela Romero M, Pombo Romero J, Bugarín González R, Tasende Souto M, Represa Veiga S: Utilización de los inhibidores de la acetilcolinesterasa y la memantina para el tratamiento clínico de la demencia tipo Alzheimer. Rev Esp Salud Publica 2005; 79: 665-672.
13. Alander J, Lönnroos E, Hartikainen S, Klaukka T: Nationwide use of medicines for Alzheimeŕs disease by community dwelling persons in Finland. J Am Geriatr Soc 2006; 54: 557-558.
14. García García FJ, Sánchez Ayala MI, Pérez Martín A, Martín Correa E, Marsal Alonso C, Rodríguez Ferrer G, et al: Prevalencia de demencia y de sus subtipos principales en sujetos mayores de 65 años: efecto de la educación y ocupación. Estudio Toledo. Med Clin 2001; 116: 401-407.
15. Fernández M, Castro-Flores J, Pérez de las Heras S, Mandaluniz-Lekumberri A, Gordejuela M, Zarranz J: Prevalencia de la demencia en mayores de 65 años en una comarca del País Vasco. Rev Neurol 2008; 46: 89-96.
16. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al: Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999; 53: 1992-1997.
17. Lobo A, Saz P, Marcos G, Día JL, de la Cámara C: The prevalence of dementia and depression in the elderly community in a southern European population: the Zaragoza study. Arch Gen Psychiatry 1995; 52: 497-506.
18. Waldemar G, Phung KT, Burns A, Georges J, Hansen FR, Iliffe S, et al: Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 2007; 22: 47-54.
19. Belle S, Zhang S, Czaja SJ, Burns R, Schulz R: Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the resources for enhancing Alzheimer's caregiver health (REACH) project. Am J Geriatr Psychiatry 2004; 12: 250-257.
20. Perras C, Shukla VK, Lessard C, Skidmore B, Bergman H, Gauthier S: Cholinesterase inhibitors for Alzheimer's disease: a systematic review of randomized controlled trials. Technology Report No 58. Ottawa, Canadian Coordinating Office for Health Technology Assessment, 2005.
21. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;-1:CD005593. DOI: 10.1002/ 14651858.CD005593. (Pubitemid 46841366)
22. Lanctôt KL, Herrmann N, Kenneth KY, Khan L, Liu BA, Loulou MM, et al: Efficacy and safety of cholinesterase inhibitors in Alzheimeŕs disease: a meta-analysis. Can Med Assoc J 2003; 169: 557-564.
23. Ritchie CW, Ames D, Clayton T, Lai R: Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 358-369.
24. Gil-Néciga E, Gobartt AL: Patrón de tratamiento de la enfermedad de Alzheimer con inhibidores colinesterásicos. Rev Neurol 2008; 46: 461-464.
25. Wennberg JE, Gittelsohn A: Small area variations in health care delivery: a populationbased health information system can guide planning and regulatory decision-making. Science 1973; 18: 1102-1108.
26. van Marum RJ: Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol 2008; 22: 265-274.
27. Burns A, O'Brien J: Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006; 20: 732-755.
28. Kaduszkiewicz H, Zimmermann T, Beck- Bornholdt HP, Bussche H: Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-327.
29. AD2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 2004; 363: 2105-2115.
30. National Institute for Health and Clinical Excellence: Appraisal consultation document: Alzheimer's disease - donepezil, rivastigmine and memantine (review). http:// www.nice.org.uk/page.aspx?o=245912 (accessed April 15, 2005).
31. Shire Pharmaceuticals: Permission granted to challenge the High Court ruling to restrict Alzheimer's drugs access on the NHS (press release). 2007. //www.shire.com/shire/ uploads/press/shire/20071206JRAppeal DecisionPermission. pdf (accessed January 7, 2008).
32. National Institute for Health and Clinical Excellence: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review). http://www. nice.org.uk/TA111 (accessed June 25, 2008).
33. Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, et al: Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging 2005; 22(suppl 1):1-26.
34. Burns A, O'Brien J: Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006; 20: 732-755.
35. Lyketsos CG, Colenda CC, Beck C, Blank K, Doraiswamy MP, Kalunian DA, et al: Task force of American Association of Geriatric Psychiatry: Position Statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006; 14: 561-572.
36. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B, EFNS: Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007; 14:e1-e26.